MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $13.60 (115.53% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016Robert W. BairdInitiated CoverageNeutral$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Brean CapitalReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016MizuhoReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Cantor FitzgeraldReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015GuggenheimInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2014JPMorgan Chase & Co.Reiterated RatingOverweight$15.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/28/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha